Strong Efficacy of Ritlecitinib 50 mg and Baricitinib 4 mg in Alopecia Areata, but Further Research Needed to Establish Superiority
May 2025
in “
Journal of the European Academy of Dermatology and Venereology
”
Studysummary This review by Aceituno et al. found that both baricitinib and ritlecitinib demonstrate strong efficacy for severe alopecia areata, with meaningful hair regrowth by Week 24, but notes limitations like differing trial sizes and potential effect size overestimations.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on onlinelibrary.wiley.com →